Atavistik Bio
MA - CambridgeBiotechnology
Focus: Atavistik Bio is a Cambridge-based biotech company focused on high-throughput screening platforms to identify allosteric modulators of proteins, with early-stage oncology programs.
Profile data last refreshed 6h ago · AI intelligence enriched 2w ago
Open Jobs
2
Should You Work at Atavistik Bio?
AI assessmentAtavistik Bio is a high-risk, high-reward early-stage play best suited for scientists seeking platform innovation and equity upside over near-term salary security.
Why Work Here
- Ground-floor opportunity at an early-stage biotech with a differentiated platform technology (allosteric modulation screening) in oncology
- Recent board appointment of Habib Dable and FDA clearance milestone (June 2026) signal investor confidence and regulatory momentum
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ATV-1601
Advanced Solid TumorsClinical Trials (2)
NCT07601425Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
Phase 1/2Help build intelligence for Atavistik Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.